Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. (Q55067016)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 February 2015

Language	Label	Description	Also known as
English	Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.	scientific article published on 24 February 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25707392

Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25707392

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

Antoni Berenguer-Llergo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

L Paré-Brunet

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

A Sebio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

J Salazar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

E Río

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

A Barnadas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

M Baiget

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

D Páez

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

24 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25707392

The Pharmacogenomics Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

397-404

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25707392%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

https://scigraph.springernature.com/pub.10.1038/tpj.2015.1

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

VEGF receptor signalling - in control of vascular function

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

The KISS1 metastasis suppressor: a good night kiss for disseminated cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Power and sample size calculations for SNP association studies with censored time-to-event outcomes

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Detecting multiple associations in genome-wide studies

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

The control of the false discovery rate in multiple testing under dependency

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Unbiased Recursive Partitioning: A Conditional Inference Framework

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.1

21 January 2018

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25707392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/25707392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Manipulating HapMap Data Using HaploView

1 reference

https://pubmed.ncbi.nlm.nih.gov/25707392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25707392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55067016&oldid=1499429713"